The genomic landscape of retinoblastoma: A review

Clinical and Experimental Ophthalmology

Volumn 42, Issue 1, 2014, Pages 33-52

  Thériault, Brigitte L ^a   Dimaras, Helen ^b,d,e   Gallie, Brenda L ^a,b,c,d   Corson, Timothy W ^f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytogenetics; Epigenetics; MicroRNA; Retinoblastoma; Single nucleotide polymorphism

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CADHERIN; CADHERIN 11; DEK PROTEIN; DNA BINDING PROTEIN; KIF14 PROTEIN; KINESIN; MEMBRANE PROTEIN; MICRORNA; MYCN PROTEIN; ONCOPROTEIN; PROTEIN MDMX; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME 2P; CLINICAL PRACTICE; DISEASE ASSOCIATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC DISORDER; GENOMICS; HUMAN; METHYLATION; MICROARRAY ANALYSIS; NEUROBLASTOMA; NONHUMAN; RETINOBLASTOMA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

CYTOGENETICS; EPIGENETICS; MICRORNA; RETINOBLASTOMA; SINGLE NUCLEOTIDE POLYMORPHISM;

GENES, TUMOR SUPPRESSOR; GENOME, HUMAN; GENOMICS; HUMANS; MICRORNAS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 84892552108     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12132     Document Type: Review

References (109)

1. Dimaras H, Kimani K, Dimba EA etal. Retinoblastoma. Lancet 2012; 379: 1436-1446.
2. Saxena P, Kaur J. Differential expression of genes in retinoblastoma. Clin Chim Acta 2011; 412: 2015-2021.
3. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68: 820-823.
4. Richter S, Vandezande K, Chen N etal. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 2003; 72: 253-269.
5. Rushlow D, Piovesan B, Zhang K etal. Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat 2009; 30: 842-851.
6. Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93: 1129-1131.
7. Eng C, Li FP, Abramson DH etal. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85: 1121-1128.
8. Comings DE. A general theory of carcinogenesis. Proc Natl Acad Sci U S A 1973; 70: 3324-3328.
9. Dryja TP, Friend S, Weinberg RA. Genetic sequences that predispose to retinoblastoma and osteosarcoma. Symp Fundam Cancer Res 1986; 39: 115-119.
10. Lee WH, Shew JY, Hong FD etal. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987; 329: 642-645.
11. Friend SH, Bernards R, Rogelj S etal. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-646.
12. Dunn JM, Phillips RA, Becker AJ, Gallie BL. Identification of germline and somatic mutations affecting the retinoblastoma gene. Science 1988; 241: 1797-1800.
13. Dimaras H, Khetan V, Halliday W etal. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 2008; 17: 1363-1372.
14. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 2007; 46: 617-634.
15. Bowles E, Corson TW, Bayani J etal. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer 2007; 46: 118-129.
16. Zielinski B, Gratias S, Toedt G etal. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 2005; 43: 294-301.
17. Corson TW, Gallie BL. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 2006; 119: 1088-1094.
18. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 2005; 24: 4741-4753.
19. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL. KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 2007; 13: 3229-3234.
20. Theriault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int J Cancer 2012; 130: 1844-1854.
21. Laurie NA, Donovan SL, Shih CS etal. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-66.
22. Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006; 45: 72-82.
23. Pajovic S, Corson TW, Spencer C etal. The TAg-RB murine retinoblastoma cell of origin has immunohistochemical features of differentiated Muller glia with progenitor properties. Invest Ophthalmol Vis Sci 2011; 52: 7618-7624.
24. Madhavan J, Mitra M, Mallikarjuna K etal. KIF14 and E2F3 mRNA expression in human retinoblastoma and its phenotype association. Mol Vis 2009; 15: 235-240.
25. Ahmed SM, Theriault BL, Uppalapati M etal. KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. J Cell Biol 2012; 199: 951-967.
26. Ganguly A, Nichols KE, Grant G, Rappaport E, Shields C. Molecular karyotype of sporadic unilateral retinoblastoma tumors. Retina 2009; 29: 1002-1012.
27. Mairal A, Pinglier E, Gilbert E etal. Detection of chromosome imbalances in retinoblastoma by parallel karyotype and CGH analyses. Genes Chromosomes Cancer 2000; 28: 370-379.
28. Sampieri K, Amenduni M, Papa FT etal. Array comparative genomic hybridization in retinoma and retinoblastoma tissues. Cancer Sci 2009; 100: 465-471.
29. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2012; 13: 83-96.
30. Gratias S, Schuler A, Hitpass LK etal. Genomic gains on chromosome 1q in retinoblastoma: consequences on gene expression and association with clinical manifestation. Int J Cancer 2005; 116: 555-563.
31. de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB etal. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. Pediatr Blood Cancer 2012; 59: 39-43.
32. McEvoy J, Ulyanov A, Brennan R etal. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PloS ONE 2012; 7: e42739.
33. Wynendaele J, Bohnke A, Leucci E etal. An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 2010; 70: 9641-9649.
34. Schwab M, Alitalo K, Klempnauer KH etal. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245-248.
35. Rushlow DE, Mol BM, Kennett JY etal. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 2013; 14: 327-334.
36. Paderova J, Orlic-Milacic M, Yoshimoto M, da Cunha Santos G, Gallie B, Squire JA. Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genet Cytogenet 2007; 179: 102-111.
37. Grasemann C, Gratias S, Stephan H etal. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 2005; 24: 6441-6449.
38. Marchong MN, Chen D, Corson TW etal. Minimal 16q genomic loss implicates cadherin-11 in retinoblastoma. Mol Cancer Res 2004; 2: 495-503.
39. Laurie N, Mohan A, McEvoy J etal. Changes in retinoblastoma cell adhesion associated with optic nerve invasion. Mol Cell Biol 2009; 29: 6268-6282.
40. Marchong MN, Yurkowski C, Ma C, Spencer C, Pajovic S, Gallie BL. Cdh11 acts as a tumor suppressor in a murine retinoblastoma model by facilitating tumor cell death. Plos Genet 2010; 6: e1000923.
41. Conkrite K, Sundby M, Mukai S etal. miR-17∼92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev 2011; 25: 1734-1745.
42. Nittner D, Lambertz I, Clermont F etal. Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol 2012; 14: 958-965.
43. Zhang J, Benavente CA, McEvoy J etal. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481: 329-334.
44. Marine JC, Jochemsen AG. Mdmx and Mdm2: brothers in arms? Cell Cycle 2004; 3: 900-904.
45. Laurie NA, Shih CS, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets 2007; 7: 689-695.
46. Guo Y, Pajovic S, Gallie BL. Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma. Biochem Biophys Res Commun 2008; 375: 1-5.
47. To KH, Pajovic S, Gallie BL, Theriault BL. Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development. BMC Cancer 2012; 12: 69.
48. Carleton M, Mao M, Biery M etal. RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol Cell Biol 2006; 26: 3853-3863.
49. Gruneberg U, Neef R, Li X etal. KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol 2006; 172: 363-372.
50. Thériault BL, Corson TW. KIF14 (kinesin family member 14). Atlas Genet Cytogenet Oncol Haematol 2012; 16: 695-699.
51. Markowski J, Oczko-Wojciechowska M, Gierek T etal. Gene expression profile analysis in laryngeal cancer by high-density oligonucleotide microarrays. J Physiol Pharmacol 2009; 60 (Suppl. 1): 57-63.
52. Markowski J, Tyszkiewicz T, Jarzab M etal. Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol 2009; 266: 1501-1507.
53. Basavarajappa HD, Corson TW. KIF14 as an oncogene in retinoblastoma: a target for novel therapeutics? Future Med Chem 2012; 4: 2149-2152.
54. Woo CW, Tan F, Cassano H, Lee J, Lee KC, Thiele CJ. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer 2008; 50: 208-212.
55. Barr FG, Duan F, Smith LM etal. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer 2009; 48: 661-672.
56. Bayani J, Zielenska M, Marrano P etal. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000; 93: 437-448.
57. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001; 81: 717-723.
58. Nau MM, Brooks BJ Jr, Carney DN etal. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A 1986; 83: 1092-1096.
59. Dietzsch E, Lukeis RE, Vrazas V, Hasthorpe S, Garson OM. Characterization of homogeneously staining regions in a small cell lung cancer cell line, using in situ hybridization with an MYCN probe. Genes Chromosomes Cancer 1994; 10: 213-216.
60. Salido M, Arriola E, Carracedo A etal. Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping. Cancer Genet Cytogenet 2009; 191: 97-101.
61. Fix A, Lucchesi C, Ribeiro A etal. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes Cancer 2008; 47: 819-834.
62. Moreau LA, McGrady P, London WB etal. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res 2006; 12: 5693-5697.
63. Godbout R, Packer M, Bie W. Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines. J Biol Chem 1998; 273: 21161-21168.
64. Godbout R, Squire J. Amplification of a DEAD box protein gene in retinoblastoma cell lines. Proc Natl Acad Sci U S A 1993; 90: 7578-7582.
65. Weber A, Imisch P, Bergmann E, Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 2004; 22: 2681-2690.
66. Carro MS, Spiga FM, Quarto M etal. DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006; 5: 1202-1207.
67. von Lindern M, Fornerod M, van Baal S etal. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992; 12: 1687-1697.
68. Privette Vinnedge LM, Ho SM, Wikenheiser-Brokamp KA, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PloS ONE 2012; 7: e46985.
69. Privette Vinnedge LM, Kappes F, Nassar N, Wells SI. Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle 2013; 12: 51-66.
70. Vimala K, Sundarraj S, Sujitha MV, Kannan S. Curtailing overexpression of E2F3 in breast cancer using siRNA (E2F3)-based gene silencing. Arch Med Res 2012; 43: 415-422.
71. Olsson AY, Feber A, Edwards S etal. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007; 26: 1028-1037.
72. Kashima T, Nakamura K, Kawaguchi J etal. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 2003; 104: 147-154.
73. Kawaguchi J, Takeshita S, Kashima T, Imai T, Machinami R, Kudo A. Expression and function of the splice variant of the human cadherin-11 gene in subordination to intact cadherin-11. J Bone Miner Res 1999; 14: 764-775.
74. Roylance R, Gorman P, Papior T etal. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 2006; 25: 6544-6553.
75. Delic S, Lottmann N, Jetschke K, Reifenberger G, Riemenschneider MJ. Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol 2012; 38: 201-212.
76. Li L, Ying J, Li H etal. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene 2012; 31: 3901-3912.
77. Carmona FJ, Villanueva A, Vidal A etal. Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol 2012; 228: 230-240.
78. Gratias S, Rieder H, Ullmann R etal. Allelic loss in a minimal region on chromosome 16q24 is associated with vitreous seeding of retinoblastoma. Cancer Res 2007; 67: 408-416.
79. Livide G, Epistolato MC, Amenduni M etal. Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. Pathol Oncol Res 2012; 18: 703-712.
80. Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR, Kumar A. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics 2007; 90: 344-353.
81. Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis 2010; 16: 1292-1303.
82. Yendamuri S, Trapasso F, Calin GA. ARLTS1 - a novel tumor suppressor gene. Cancer Lett 2008; 264: 11-20.
83. Tosi GM, Trimarchi C, Macaluso M etal. Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach. Oncogene 2005; 24: 5827-5836.
84. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev 2004; 18: 1681-1694.
85. Priya K, Jada SR, Quah BL, Quah TC, Lai PS. High incidence of allelic loss at 16q12.2 region spanning RBL2/p130 gene in retinoblastoma. Cancer Biol Ther 2009; 8: 714-717.
86. Xu XL, Fang Y, Lee TC etal. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 2009; 137: 1018-1031.
87. Kato MV, Shimizu T, Ishizaki K etal. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett 1996; 106: 75-82.
88. Castera L, Sabbagh A, Dehainault C etal. MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst 2010; 102: 1805-1808.
89. Epistolato MC, Disciglio V, Livide G etal. p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma. J Hum Genet 2011; 56: 685-686.
90. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-365.
91. Temming P, Corson TW, Lohmann DR. Retinoblastoma tumorigenesis: genetic and epigenetic changes walk hand in hand. Future Oncol 2012; 8: 525-528.
92. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989; 83: 155-158.
93. Reis AH, Vargas FR, Lemos B. More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma. Front Genet 2012; 3: 284.
94. Choy KW, Lee TC, Cheung KF etal. Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma. Neoplasia 2005; 7: 200-206.
95. Harada K, Toyooka S, Maitra A etal. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002; 21: 4345-4349.
96. Liu R, Gao L, Lu GX, Tang LS, Zhu XH, Wang J. [Methylation status of RASSF1A and DAPK promoter in retinoblastoma]. Zhonghua Yan Ke Za Zhi 2009; 45: 631-635.
97. Choy KW, Pang CP, To KF, Yu CB, Ng JS, Lam DS. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues. Invest Ophthalmol Vis Sci 2002; 43: 1344-1349.
98. Indovina P, Acquaviva A, De Falco G etal. Downregulation and aberrant promoter methylation of p16INK4A: a possible novel heritable susceptibility marker to retinoblastoma. J Cell Physiol 2010; 223: 143-150.
99. Huang JC, Babak T, Corson TW etal. Using expression profiling data to identify human microRNA targets. Nat Methods 2007; 4: 1045-1049.
100. Mu G, Liu H, Zhou F etal. Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol 2010; 41: 493-502.
101. Zhao JJ, Yang J, Lin J etal. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009; 25: 13-20.
102. Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest Ophthalmol Vis Sci 2009; 50: 4542-4551.
103. Li BQ, Zhang J, Huang T, Zhang L, Cai YD. Identification of retinoblastoma related genes with shortest path in a protein-protein interaction network. Biochimie 2012; 94: 1910-1917.
104. Martin J, Bryar P, Mets M etal. Differentially expressed miRNAs in retinoblastoma. Gene 2013; 512: 294-299.
105. Beta M, Venkatesan N, Vasudevan M, Vetrivel U, Khetan V, Krishnakumar S. Identification and insilico analysis of retinoblastoma serum microRNA profile and gene targets towards prediction of novel serum biomarkers. Bioinform Biol Insights 2013; 7: 21-34.
106. Jo DH, Kim JH, Park WY, Kim KW, Yu YS, Kim JH. Differential profiles of microRNAs in retinoblastoma cell lines of different proliferation and adherence patterns. J Pediatr Hematol Oncol 2011; 33: 529-533.
107. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 2010; 285: 36721-36735.
108. Wu J, Qian J, Li C etal. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 2010; 9: 1809-1818.
109. Dimaras H, Rushlow D, Halliday W etal. Using RB1 mutations to assess minimal residual disease in metastatic retinoblastoma. Transl Res 2010; 156: 91-97.